AmSurg Corp. (AMSG): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report


AmSurg's third-quarter 2014 adjusted EPS of $0.66 increased 24.5% year over year sailing past the Zacks Consensus Estimate of $0.54. It has also exceeded the company's guidance range. Revenues increased a massive 91.3% but failed to meet the estimate. Apart from strong performance of Sheridan, improved average revenues per procedure and increase in same-center revenues were encouraging. The Sheridan acquisition has paved AmSurg's way into the huge and fast-growing fragmented physician outsourcing market. Nonetheless, headwinds like reduction in workers' compensation reimbursement, sequestration and increased interest expense are intimidating. We are thus Neutral on AmSurg.


Headquartered in Nashville, TN, AmSurg Corporation (AMSG) is a leading operator of single-specialty practice-based ambulatory surgery centers (ASCs). The company develops, acquires, and operates practice-based ASCs in partnership with physician practice groups throughout the U.S.

At the end of Mar 2014, AmSurg operated 242 ASCs located in 35 states and the District of Columbia. Among these ASCs, the company owned majority interest in 235 centers and owned a minority interest in seven (three of which are consolidated).

At the end of Mar 2014, 151 centers performed gastrointestinal endoscopy procedures, 48 performed procedures in multiple specialties, 36 performed ophthalmology procedures and seven centers performed orthopedic procedures.

Sources of Revenues

Revenues are derived entirely from facility fee charges, which are largely funded by third-party reimbursement programs such as government and private insurance. The fee varies depending on the procedure but usually includes all charges for operating room usage, special equipment usage, supplies, recovery room usage, nursing staff and medication and in some cases, billing for anesthesia services. However, it does not include consultation charges of the surgeon, anesthesiologist or other attending physicians for patients as these are billed directly by the physicians themselves. In 2013, AmSurg derived approximately 25% of revenues from governmental healthcare programs, primarily Medicare and Medicare managed programs, and the remainder from a wide mix of commercial payors and patient co-pays and deductibles.

AmSurg Corp. (AMSG): Read the Full Research Report
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AMSURG CORP (AMSG): Free Stock Analysis Report

To read this article on click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ, Inc.

This article appears in: Investing , Stocks

Referenced Stocks: AMSG

More from

Related Videos




Most Active by Volume

  • $15.38 ▼ 1.09%
  • $110.38 ▲ 0.73%
  • $104.01 ▲ 1.75%
  • $6.3801 ▼ 53.60%
  • $4.25 ▲ 4.94%
  • $15.91 ▲ 7.72%
  • $4.64 ▲ 11.27%
  • $25.47 ▲ 1.11%
As of 10/2/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by